BUSINESSCNBC TOP
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical company AstraZeneca is in talks with U.S. rival Bristol Myers Squibb for a potential $400 billion merger, as reported by the Financial Times.
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca Said to Have Explored Bristol Myers Merger
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
- Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration